Lexigor

Omeprazole, the active ingredient in Lexigor, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is used to treat acid‑related disorders such as gastroesophageal reflux disease, peptic ulcer disease and erosive esophagitis.

GNH USA supplies Lexigor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is indicated for several acid‑related gastrointestinal conditions. - Gastroesophageal reflux disease (GERD): provides symptomatic relief by decreasing gastric acid exposure to the esophagus. - Peptic ulcer disease: promotes ulcer healing through sustained acid suppression. - Erosive esophagitis: allows mucosal recovery by maintaining a higher gastric pH. - Helicobacter pylori eradication: used in combination therapy to enhance bacterial eradication rates.

Common adverse reactions are generally mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: discomfort in the upper abdomen. - Nausea: feeling of queasiness. - Diarrhea: loose stools. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis, angioedema. - Clostridioides difficile infection: severe colitis. - Hypomagnesemia: low serum magnesium levels. - Bone fractures: increased risk with long‑term use. - Interstitial nephritis: kidney inflammation. - Stevens‑Johnson syndrome: severe skin reaction.

Before initiating therapy, consider the following safety measures. - Renal function assessment: adjust use in severe renal impairment. - Elderly patients: monitor for increased sensitivity to side effects. - Long‑term therapy: evaluate need periodically to minimize risks. - Drug interaction review: check concomitant medications that may affect acid levels. - Discontinuation: avoid abrupt cessation after prolonged use to prevent rebound acid hypersecretion. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole may alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Atazanavir, nelfinavir, rilpivirine: reduced absorption and efficacy. - Clopidogrel: decreased activation leading to reduced antiplatelet effect. - Warfarin: potential increase in INR and bleeding risk.

Moderate Interactions (Monitor Closely): - Diazepam, phenytoin, digoxin: altered plasma concentrations requiring dose adjustments. - Methotrexate: increased exposure may raise toxicity risk. - Ketoconazole: decreased absorption, may require alternative antifungal therapy.